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Abstract: Lupus is a chronic, systemic inflammatory condition in which eicosanoids, 
  cytokines, nitric oxide (NO), a deranged immune system, and genetics play a significant role. 
Our studies revealed that an imbalance in the pro- and antioxidants and NO and an alteration 
in the metabolism of essential fatty acids exist in lupus. The current strategy of management 
includes administration of nonsteroidal anti-inflammatory drugs such as hydroxychloroquine and 
immunosuppressive drugs such as corticosteroids. Investigational drugs include the   following: 
1) belimumab, a fully human monoclonal antibody that specifically recognizes and inhibits 
the biological activity of B-lymphocyte stimulator, also known as B-cell-activation factor of 
the TNF family; 2) stem cell transplantation; 3) rituximab, a chimeric monoclonal antibody 
against CD20, which is primarily found on the surface of B-cells and can therefore destroy 
B-cells; and 4) IL-27, which has potent anti-inflammatory actions. Our studies showed that a 
regimen of corticosteroids and cyclophosphamide, and methods designed to enhance endothelial 
NO synthesis and augment antioxidant defenses, led to induction of long-lasting remission of 
the disease. These results suggest that methods designed to modulate molecular signatures of 
the disease process and suppress inflammation could be of significant benefit in lupus. Some 
of these strategies could be vagal nerve stimulation, glucose–insulin infusion, and administra-
tion of lipoxins, resolvins, protectins, and nitrolipids by themselves or their stable synthetic 
analogs that are known to suppress inflammation and help in the resolution and healing of the 
inflammation-induced damage. These strategies are likely to be useful not only in lupus but 
also in other conditions, such as rheumatoid arthritis, scleroderma, ischemia-reperfusion injury 
to the myocardium, ischemic heart disease, and sepsis.
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Introduction
Systemic lupus erythematosus (SLE), a disease of unknown etiology that is more 
common in women than in men, is characterized by nondestructive arthritis/arthral-
gias, a cutaneous rash, vasculitis, involvement of the central nervous system (CNS), 
and renal and cardiopulmonary manifestations. Although genetic, environmental, and 
sex hormonal factors have been implicated in the pathogenesis of SLE (also called as 
‘lupus’), it is known that several cytokines, nitric oxide (NO), free radicals, a deranged 
immune system, deficient antioxidant defenses, and toll-like receptors have a significant 
role both in the initiation and perpetuation of the inflammatory process observed. The 
fundamental process in lupus appears to be rendering DNA and RNA antigenic, which 
leads to the production of anti-DNA and anti-RNA antibodies and the formation of Journal of Inflammation Research 2010:3
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Figure 1 Scheme showing generation of ROS and NO and formation of RNIs. 
Stimulus  could  be  injury,  infection,  foreign  particles,  or  release  of  various 
proinflammatory cytokines. A close interaction exists between NADPH oxidase 
and MPO (see the text). Superoxide anion can inactivate NO, and in turn NO can 
inactivate superoxide anion. NO and superoxide anion interact to form reactive 
nitrogen intermediates that are potent inflammatory substances. In general, iNO is 
proinflammatory, whereas eNO is anti-inflammatory in nature.
Abbreviations: MPO, myeloperoxidase; NADPH, nicotinamide adenine dinucleotide 
phosphate; PMNLs, polymorphonuclear leukocytes; RNI, reactive nitrogen intermediates; 
ROS, reactive oxygen species.
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immune complexes. These antibodies and immune complexes 
in turn trigger both a local and systemic inflammatory response 
that ultimately leads to target organ/tissue damage seen in 
lupus. The susceptibility for a given individual to develop 
lupus seems to have, at least partly, a genetic basis, though 
this is still not very clear. Once the inflammatory process is 
triggered, this leads to the production of a variety of proin-
flammatory cytokines such as interleukin (IL)-1, IL-6, tumor 
necrosis factor-α (TNF-α), interferons (IFNs), macrophage 
migration inhibitory factor (MIF), HMGB-1 (high-mobility 
group B1), and possibly a reduction in the elaboration of 
anti-inflammatory cytokines such as IL-10, IL-4, and trans-
forming growth factor-β (TGF-β). This imbalance between 
the pro- and anti-inflammatory cytokines coupled with 
increased secretion of free radicals such as superoxide anion 
(O2
−), hydrogen peroxide (H2O2), singlet oxygen, inducible 
nitric oxide (iNO), and other reactive oxygen species (ROS) 
by activated monocytes, macrophages, polymorphonuclear 
leukocytes (PMNL), T-cells, Kupffer cells, glial cells in 
the brain, and other organ-specific reticuloendothelial cells 
would ultimately cause target tissue/organ damage seen in 
lupus (see Figure 1 for the formation of free radicals, NO, 
and reactive nitrogen intermediates). No lupus patients have 
the same manifestations, and the clinical presentation of 
the same patient at different time periods could be variable. 
For example, initially, a particular patient may present with 
cutaneous manifestations and over a period of time might 
develop involvement of joints, kidneys, and other organs. 
Similarly, the response of patients with lupus and rheumatoid 
arthritis is variable. Some respond, others may not respond, 
and some show only partial response to the same therapeutic 
measures. This type of varied presentation(s) and differential 
response to the same treatment is at times baffling and suggests 
that the involvement of various organs and tissues due to the 
underlying inflammatory process is varied, and the degree of 
involvement may differ in both time and extent and, more 
importantly, is unpredictable. It is also possible that continued 
inflammatory events seen in lupus, rheumatoid arthritis (RA), 
and other rheumatological conditions could be due to failure 
of the resolution of inflammation. Thus, the balance between 
inflammation and resolution is disturbed more in favor of 
proinflammatory events and/or failure of resolution-inducing 
molecules to be produced at the most appropriate time, leading 
to nonresolution of inflammation. In other words, even after 
the inciting agent responsible for the initiation of inflamma-
tion is removed, inappropriate inflammation continues simply 
because resolution failed to occur. This leads to delay in the 
healing/repair process and so tissue/organ damage continues. 
This may explain why target organ damage continues even 
when these patients are continuing to take anti-inflammatory 
and immunosuppressive medicines. In view of this, it is 
imperative that administration of proresolution-inducing 
agents is needed to obtain full remission and restore normal 
physiological function of the target tissues/organs in these 
diseases. Such endogenous proresolution-inducing molecules 
include lipoxins (LXs), resolvins, protectins, maresins, NO, 
nitrolipids, 15 deoxy∆12–14 PGJ2, PGD2, anti-inflammatory 
cytokines such as IL-4, IL-10, and some polyunsaturated 
fatty acids (PUFAs). Hence, understanding the interaction(s) 
between proinflammatory and anti-inflammatory and prore-
solution molecules is important to devise newer therapeutic 
strategies in several inflammatory conditions.
Pathobiology of inflammation  
with specific reference  
to chronic inflammation
Inflammation is a reaction to injurious agents, either exter-
nal or internal, that consists of both vascular and cellular 
responses. Inflammation may be local or systemic, and it 
can be acute or chronic. During inflammation, the reaction of 
blood vessels is unique and leads to the accumulation of fluid 
and leukocytes in extravascular tissues. This reaction can be 
in the form of vasodilatation, which is seen as hyperemia at 
the site(s) of injury and which serves the essential function of 
increasing the blood supply to the injured tissue/organ so that Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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adequate elimination of the inflammation-inducing agent is 
achieved and/or the repair process can occur after the inflam-
mation subsides. Thus, injury and repair are two faces of the 
inflammatory process, and it is difficult to separate these two 
processes. In fact, in the majority of instances, inflammation 
to injury and repair occur almost simultaneously.1
Mediators of inflammation
Some of the important mediators of inflammation include 
  histamine, serotonin, lysosomal enzymes, PGs, LTs, PAFs, 
ROS, NO, HOCL, various cytokines, kinin system,   coagulation/
fibrinolysis system, and complement system.1 The role of arachi-
donic acid and other PUFAs and their products in inflammation 
deserves special mention in view of their role in inflammation, 
resolution of inflammation, and inhibition of production of 
proinflammatory cytokines, which may be relevant to their 
involvement in lupus and other rheumatological conditions.
Metabolism of essential fatty acids
Cis-linoleic acid (LA, 18:2 ω-6) and α-linolenic acid (ALA, 
18:3 ω-3) are essential nutrients because they cannot be syn-
thesized by the human body and are hence called ‘essential 
fatty acids’ (EFAs). LA is converted to γ-linolenic acid (GLA, 
18:3, ω-6) by the action of the enzyme ∆6 desaturase, and GLA 
is elongated to form dihomo-GLA (DGLA, 20:3, ω-6), the 
precursor of the 1 series of prostaglandins. ∆6 desaturase is the 
rate-limiting step in the metabolism of EFAs. DGLA can also 
be converted to arachidonic acid (AA, 20:4, ω-6) by the action 
of the enzyme ∆5 desaturase. AA forms the precursor of two 
series of prostaglandins, thromboxanes, and the four series 
of leukotrienes (LTs). ALA is converted to eicosapentaenoic 
acid (EPA, 20:5, ω-3) by ∆6 and ∆5 desaturases. EPA forms 
the precursor of the three series of prostaglandins and the five 
series of LTs. EPA can be elongated to form docosahexaenoic 
acid (DHA, 22:6, ω-3). AA, EPA, and DHA also form precur-
sors to a group of novel compounds such as LXs, resolvins, 
protectins, and   maresins2–9 that exhibit   anti-inflammatory 
action (see Figure 2 for metabolism of EFAs). Eicosanoids 
bind to G-protein-coupled receptors (GPCRs) on many cell 
types and mediate virtually every step of inflammation. They 
are found in inflammatory exudates, and their synthesis is 
increased at sites of inflammation. Nonsteroidal anti-inflam-
matory drugs (NSAIDs) such as aspirin inhibit cyclooxyge-
nase (COX) activity and are thus believed to bring about their 
anti-inflammatory action, though this has been disputed. On 
the basis of the involvement of eicosanoids in inflammation, 
COX-2 inhibitors have been developed. However, recent 
studies showed that COX-2 inhibitors enhance cardiovascular 
events,6,10 suggesting that there is a close interaction between 
eicosanoids and cardiovascular system.
Lipoxins, resolvins, protectins,  
and maresins
There are two COX enzymes: the constitutively expressed 
COX-1 and the inducible enzyme COX-2. Different types of 
PGs are formed by the action of COX enzymes   de  pending on 
the substrate fatty acid from which they are derived.   Different 
types of PGs exhibit different actions and sometimes diametri-
cally opposite actions. For example, PGE2, PGF2α, thrombox-
ane A2 (TXA2), and LTs exhibit proinflammatory actions, 
whereas PGE1 and prostacyclin (PGI2) show anti-inflammatory 
actions. Furthermore, the distributions of COX-1 and COX-2 
enzymes have restricted tissue distribution. Platelets contain 
thromboxane synthetase, and hence TXA2, a potent platelet 
aggregator and vasoconstrictor, is formed in these cells, 
whereas vascular endothelial cells possess PGI2 synthetase but 
lack thromboxane synthetase and thus they mainly form, PGI2, 
a potent platelet antiaggregator and vasodilator. The balance 
between TXA2 and PGI2 is important in thrombus formation 
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in coronary and cerebral blood vessels. PGE2 is hyperalgesic, 
causes a marked increase in pain produced by intradermal 
injection of suboptimal concentrations of histamine and 
bradykinin, and is involved in cytokine-induced fever during 
infections. PGD2, PGE2, and PGF2α, major metabolites of the 
COX pathway in mast cells, cause vasodilatation and increase 
the permeability of postcapillary venules, thus potentiating 
edema formation. COX-2 enzyme is absent in most tissues 
under normal ‘resting’ conditions and is expressed only in 
response to proinflammatory stimuli, whereas COX-1 is 
constitutively expressed in most tissues. Thus, PGs produced 
by COX-1 serve a homeostatic function (such as fluid and 
electrolyte balance in the kidneys and cytoprotection in the 
gastrointestinal tract), whereas COX-2 stimulates the produc-
tion of the PGs that are involved in inflammatory reactions.
There are three types of lipoxygenases and they are   present 
in only a few types of cells. 5-lipoxygenase (5-LO), present 
in neutrophils, produces 5-HETE, which is chemotactic for 
neutrophils and is converted into LTs. LTB4, a potent chemot-
actic and activator of neutrophils, induces   aggregation and 
adhesion of leukocytes to vascular endothelium,   genera  tion 
of ROS, and release of lysosomal enzymes. The cysteinyl-
containing LTs C4, D4, and E4 (LTC4, LTD4, and LTE4) induce 
vasoconstriction, bronchospasm, and vascular permeability 
in venules. LTs are more potent than histamine in increas-
ing vascular permeability and causing bronchospasm. LTs 
mediate their actions by binding to cysteinyl leukotriene 1 
(CysLT1) and CysLT2 receptors.
LXs are generated from AA, EPA, and DHA by transcel-
lular biosynthetic mechanisms involving two cell popula-
tions. Neutrophils produce intermediates in LX synthesis, 
and these are converted to LXs by platelets interacting with 
leukocytes. LXA4 and LXB4 are generated by the action 
of platelet 12-lipoxygenase on neutrophil-derived LTA4. 
LXs inhibit leukocyte recruitment, neutrophil chemotaxis, 
and adhesion to endothelium.7 LXs have a negative regula-
tion on LT synthesis and action and help in the resolution 
of inflammation. An inverse relationship generally exists 
between LXs and LTs, and the balance between these two 
molecules appears to be crucial in the determination of degree 
of inflammation and its final resolution (see Figures 3–7 for 
the formation of LXs, resolvins, and protectins).
Aspirin-triggered 15 epimer  
LXs, resolvins, and protectins
Aspirin-triggered 15 epimer LXs (ATLs) are potent counter-
regulators of polymorphonuclear neutrophils (PMNs)-mediated 
injury and acute inflammation. Acetylated COX-2 enzyme of 
endothelial cells generates 15R-hydroxyeicosatetraenoic acid 
(15R-HETE) from AA that is converted by activated PMNs 
to the 15-epimeric LXs that have potent anti-inflammatory 
properties.2–11 This cross-talk between endothelial cells and 
PMNs, leading to the formation of 15R-HETE and its sub-
sequent conversion to 15-epimeric LXs by aspirin-acetylated 
COX-2, is a protective mechanism to prevent local inflamma-
tion on the vessel wall by regulating the motility of PMNs, 
eosinophils, and monocytes.9 Endothelial cells also oxidize 
AA, EPA, and DHA via P450 enzyme system to form vari-
ous hydroxyeicosatetraenoic acids and epoxyeicosatrienoic 
acids such as 11,12-epoxy-eicosatetraenoic acid(s) that have 
many biological actions, including blocking endothelial cell 
activation, whereas nonenzymatic oxidation products of EPA 
inhibit phagocyte-endothelium interaction and suppress the 
expression of adhesion molecules6,12–17 (see Figure 8 for the 
formation of isoprostane-like compounds formed from EPA). 
The anti-inflammatory activity of EPA and its derivatives 
such as isoprostane-like compounds is supported by the 
observation that when hospitalized patients of acute guttate 
psoriasis with a minimum 10% of body surface area involve-
ment (range 10%–90%) were given an n-3 fatty acid-based 
lipid emulsion (100 mL/day with 2.1 g EPA and 21 g DHA) 
for 10 days, the severity of disease markedly decreased in all 
the patients. In these patients, platelet-activating factor (PAF) 
generation in ionophore-stimulated neutrophils on days 0, 1, 
3, 5, 10, and 40 decreased, and a more than tenfold increase 
in neutrophil EPA-derived 5-LO product formation (LTB5, 
its omega-oxidation products, nonenzymatic degradation 
products of LTA5, and 5-hydroxyeicosapentaenoic acid) was 
noted in the n-3 group. These results conclusively suggest 
that modulation of eicosanoid metabolism by intravenous Journal of Inflammation Research 2010:3
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n-3 fatty acid supplementation exerts a rapid beneficial effect 
on inflammation by forming nonenzymatic isoprostane-like 
compounds.18
It is likely that similar isoprostane-like compounds may 
also be formed from DHA. However, this needs to be firmly 
established.
Akin to the formation of 15R-HETE and 15-epimeric LXs 
from AA, similar compounds are also formed from EPA and 
DHA. In the presence of aspirin, activated COX-2 of human 
endothelial cells converts EPA to 18R-HEPE, 18-HEPE, and 
15R-HEPE. Activated human PMNs in turn converted 18R-
HEPE to 5,12,18R-triHEPE and 15R-HEPE to 15-  epi-LXA5 Journal of Inflammation Research 2010:3
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by their 5-LO. Both 18R-HEPE and 5,12,18R-triHEPE 
inhibited LTB4-stimulated PMN transendothelial migration. 
5,12,18R-triHEPE effectively competed with LTB4 for its 
receptors and inhibited PMN infiltration, suggesting that it 
suppresses LT-mediated responses at the sites of inflamma-
tion (reviewed in Das6 and Serhan et al19,20).
The conversion of EPA by human endothelial cells 
with upregulated COX-2 treated with ASA of EPA to 
15-epi-LX, also termed aspirin-triggered LX (ATL), 
and to 18R-hydroxyeicosapentaenoic acid (HEPE) and 
  15R-HEPE is interesting. These compounds in turn are 
used by PMNLs to generate separate classes of novel 
trihydroxy-containing mediators, including 5-series 15R-
LX(5) and 5,12,18R-triHEPE, which are potent inhibitors 
of human PMNL transendothelial migration and infiltration 
in vivo (ATL   analogue . 5,12,18R-triHEPE . 18R-HEPE). 
  Acetaminophen and indomethacin also permitted 18R-HEPE 
and 15R-HEPE generation with recombinant COX-2. The 
formation of these bioactive lipid mediators via COX-2-
NSAID-dependent oxygenations and cell–cell interactions 
may have significant therapeutic benefits in inflammation, 
neoplasia, and vascular diseases.19,20
Murine brain cells expressing COX-2 and treated with 
aspirin transformed enzymatically DHA to 17R series of 
hydroxy DHAs (HDHAs), which, in turn, is converted 
enzymatically by PMNs to di- and trihydroxy-containing 
docosanoids.19–22 DHA is converted by leukocytes, brain, and 
glial cells to 17S-hydroxy-containing docosanoids denoted 
as docosatrienes (the main bioactive member of the series 
was 10,17S-docosatriene) and 17S series resolvins, and they 
serve as regulators of both leukocytes, reducing infiltration 
in vivo, and glial cells, blocking their cytokine production. 
These results indicate that DHA is the precursor to potent 
protective mediators generated via enzymatic oxygenations 
to novel docosatrienes and 17S series resolvins that have 
significant anti-inflammatory action and participate in the 
resolution of inflammatory events (see Figures 2–6 for the 
formation of LXs, resolvins, and protectins from their pre-
cursors and structures).
Similar small-molecular-weight compounds are also 
generated from AA, EPA, and DHA: 15R-hydroxyl-
  containing compounds from AA, 18R series from EPA, 
and 17R-hydroxy series from DHA. All these compounds 
have potent anti-inflammatory actions and resolve inflam-
mation and hence are called ‘resolvins.’ Resolvins inhibited 
cytokine generation, leukocyte recruitment, leukocyte dia-
pedesis, and exudate formation. The formation of resolvins 
from AA, EPA, and DHA and from acetylated COX-2 is 
generated via transcellular biosynthesis (eg, due to cell–cell 
communication between endothelial cells and PMNs), and 
their main purpose appears to be to suppress inflammation. 
Resolvins inhibited brain ischemia-reperfusion injury.21,22 It 
is possible that LXs, resolvins, and protectins (docosanoids 
are also called as protectins because they have neuroprotec-
tive actions) behave as endogenous anti-inflammatory and 
cytoprotective molecules. The general cytoprotective proper-
ties that have been attributed to AA, EPA, and DHA can be 
related to their conversion to LXs, resolvins, and docosanoids 
(protectins). Hence, any defect in the synthesis of LXs, 
resolvins, and protectins or their inappropriate degradation 
could lead to perpetuation of inflammation. This could be 
one mechanism by which acute inflammation assumes its 
chronic phase as seen in lupus and other rheumatological 
conditions.
In addition, continued production of proinflammatory 
molecules such as macrophage MIF and HMGB-1 seems 
to have a significant role in the pathobiology of lupus and 
other conditions. It is possible that both MIF and HMGB-1 
are able to overcome the anti-inflammatory actions of 
LXs, resolvins, protectins, and maresins. Alternatively, 
inadequate production of LXs, resolvins, protectins, and 
maresins may fail to suppress the production of MIF and Journal of Inflammation Research 2010:3
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HMGB-1, which may allow the inflammatory process to 
continue.
In this context, it is noteworthy that anti-inflammatory 
cytokines IL-4 and IL-10 may have the ability to trigger 
the conversion of AA, EPA, and DHA to LXs, resolvins, 
protectins, and maresins, suggesting a mechanism by which 
they are able to suppress inflammation.23 For example, it was 
shown that IL-4 upregulated 15-LO gene expression in human 
leukocytes. (It may be noted here that 15-S-HETE (a 15-LO 
product; LO = lipoxygenase enzyme) and LXs (interaction Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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products between 5-LO and either 12-LO or 15-LO) coun-
teract the proinflammatory actions of LTs.) Glomerular 
12/15-LO mRNA increased significantly over controls 24 and 
48 h after nephrotoxic serum injection then decreased at 72 h. 
RNA from nephrotoxic-serum-injected glomeruli contained 
higher levels of 12/15-LO mRNA than that from unstimulated 
peripheral leukocytes, suggesting that 12/15-LO transcription 
is upregulated locally in native and/or infiltrating glomeru-
lar cells. Glomerular IL-4 mRNA increased markedly 16 
h post-nephrotoxic serum injection, and was then reduced, 
suggesting a potential role for T-  cell-derived IL-4 in direct-
ing the expression of 12/15-LO during glomerulonephritis. 
This suggested tandem-regulated in vivo gene expression for 
IL-4 and LO, both of which promote counterinflammatory 
influences in immune complex-mediated injury.
The 5-lipoxygenated metabolites of AA, the LTs, are 
major mediators of early glomerular hemodynamic and 
structural deterioration during experimental glomerulone-
phritis, which is generated largely by infiltrating leukocytes 
but can also occur by intrinsic glomerular cells via trans-
cellular metabolism of intermediates. In animal models of 
glomerulonephritis and other renal pathologic states, LTs 
have been shown to exert adverse effects in the glomeru-
lus. LTB4 augments neutrophil infiltration, and LTC4 and 
LTD4 mediate potent vasoconstrictor effects on the glomeru-
lar microcirculation. Selective blockade of the 5-LO pathway 
produced a significant amelioration of the deterioration of 
renal hemodynamic and structural parameters. On the other 
hand, 15-S-hydroxyeicosatetraenoic acid (15-S-HETE), the 
immediate product of arachidonate 15-lipoxygenase, and the 
LXs, which are produced by sequential 15- and 5- or 5- and 
12-lipoxygenation of AA, are also generated in the course 
of glomerular injury that antagonizes LT-induced neutro-
phil chemotaxis, and lipoxin A4 antagonizes the effects of 
LTD4 and LTC4 on the glomerular microcirculation. Thus, 
the contrasting effects of 5- and 15-lipoxygenase products 
represent endogenous pro- and anti-inflammatory influences 
that ultimately determine and regulate the extent and sever-
ity of glomerular inflammation.24–27
These results are in favor of the proposal that anti-
  inflammatory cytokines IL-4 and IL-10 induce the expression 
and synthesis of anti-inflammatory lipid mediators such as LXs, 
resolvins, protectins, and maresins in addition to their ability 
to suppress the production of proinflammatory cytokines such 
as IL-2, IL-6, TNF-α, MIF and HMGB-1, and LTs.
It is also relevant to note that monocytes and macrophages 
express an extensive repertoire of GPCRs that regulate 
inflammation and immunity.
A number of GPCRs (eg, Edg5, P2ry2, and 6) have been 
reported to be expressed by macrophages and two cell types 
closely related to macrophages (osteoclasts and dendritic 
cells), whereas Gpr84 expression was largely restricted 
to macrophage populations and granulocytes.28 It is now 
apparent that many PUFAs, especially AA, EPA, and DHA, 
and their metabolites, such as eicosanoids, LXs, resolvins, 
protectins, and maresins, also function directly as agonists 
at a number of GPCRs. Tissue distribution studies and 
siRNA knockdown experiments have indicated key roles 
for these GPCRs in glucose homeostasis, adipogenesis, 
leukocyte recruitment, and inflammation.29 A recent study 
showed that the GPCR120 functions as a ω-3 fatty acid 
receptor/sensor. Stimulation of GPR120 with ω-3 fatty acids 
(EPA and DHA) induced broad anti-inflammatory effects 
in monocytic RAW 264.7 cells and in primary intraperito-
neal macrophages. All of these effects were abrogated by 
GPR120 knockdown. The ω-3 fatty acid treatment not only 
inhibited inflammation but also enhanced systemic insulin 
sensitivity in wildtype mice, but was without effect in 
GPR120 knockout mice. These results suggest that GPR120 
is a functional ω-3 fatty acid receptor/sensor and mediates 
potent insulin-sensitizing and antidiabetic effects in vivo 
by repressing macrophage-induced tissue inflammation.30 
Thus, it is likely that PUFAs and their anti-inflammatory 
products such as LXs, resolvins, protectins, and maresins 
inhibit the production of various proinflammatory mol-
ecules, including MIF and HMGB-1, and thus suppress 
inflammation in diseases such as lupus and RA.
In view of the role of MIF and HMGB-1 in lupus and RA 
and their interaction with corticosteroids, a brief discussion 
of their role in lupus and RA is given below.
Macrophage MIF
Macrophage MIF is a potent proinflammatory molecule 
produced by T-cells, macrophages, pituitary, adrenal, 
liver, spleen, lung, and skin, and its expression correlates 
with macrophage functions such as adherence, spreading, 
phagocytosis, and tumoricidal action. MIF is a modulator of 
inflammatory and immune responses.31 MIF released by ante-
rior pituitary cells counteracts the effects of glucocorticoids 
and serves as an integral part of the host’s stress response. 
Pituitary production of MIF is induced by corticotrophin-
releasing factor in a cyclic AMP-dependent manner. MIF 
is present within the intracellular pools of macrophages and 
hence is released rapidly in response to stimulation. MIF 
promotes TNF-α, IL-1β, IL-2, IL-6, IL-8, IFN-γ, and NO 
release, enhances matrix metalloproteinase expression, and Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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induces COX-2 pathway. TNF-α production is reduced by 
antisense MIF treatment of macrophages, and MIF is a potent 
stimulant of TNF-α production. Glucocorticoids stimulate 
the release of MIF, which can override the immunosuppres-
sive effects of glucocorticoids, suggesting that MIF acts in 
concert with glucocorticoids to control the ‘set point’ of the 
immune and inflammatory response. MIF has a role in the 
development of TH2-driven antibody production and is one 
of the mediators of sepsis and septic shock because neutral-
izing anti-MIF antibodies protect experimental animals from 
severe sepsis.32–41 MIF knockout mice are relatively resistant 
to LPS-induced sepsis.
In lupus and other rheumatological conditions, a good 
correlation has been found between the severity of the dis-
ease and plasma MIF levels. In those who showed successful 
immunosuppression, MIF production became negative,35 sug-
gesting that plasma MIF levels could be used as a marker of 
response to therapy. It was reported that plasma levels of MIF 
were increased in those with active lupus and RA, indicating 
that MIF plays a key role in these diseases.42–46
HMGB-1
HMGB-1 is a nonhistone nuclear protein that is constitutively 
expressed in quiescent cells and stored in the nucleus. It is 
one of the most evolutionarily preserved proteins in eukaryo-
cytes and has been implicated in many cellular functions, 
including binding of transcription factors to their cognate 
DNA sequences. In addition to the nucleus, HMGB-1 is also 
localized to the cell membrane, where it colocalizes and inter-
acts with the receptor for advanced glycation end products 
(RAGE) and toll-like receptor-4 (TLR-4) and is released by 
activated macrophages/monocytes and functions as a late 
mediator of lethal endotoxemia and sepsis.38,39 Following 
stimulation, endotoxin, TNF-α, IL-1β, IFN-γ macrophages, 
monocytes, and pituitary cells release HMGB-1 in a time- and 
dose-dependent fashion. HMGB-1 is also released passively 
from necrotic or damaged cells and after tissue ischemia 
and reperfusion injury. Apoptotic cells do seem to release 
HMGB-1. Because autoantibodies against double-stranded 
DNA (dsDNA) and nucleosomes represent a hallmark of 
lupus, it has been suggested that impaired phagocytosis of 
apoptotic cells with consecutive release of nuclear antigens 
may contribute to the immune pathogenesis. The architectural 
chromosomal protein and HMGB-1 are tightly attached to the 
chromatin of apoptotic cells. HMGB-1 bound to nucleosomes 
released from late apoptotic cells in vitro and HMGB-1-
  nucleosome complexes were also detected in plasma from 
lupus patients. HMGB-1-containing nucleosomes from apop-
totic cells induced secretion of IL-1β, IL-6, IL-10, and TNF-α 
and expression of costimulatory molecules in macrophages 
and dendritic cells (DCs), respectively. HMGB-1-containing 
nucleosomes from apoptotic cells induced anti-dsDNA and 
antihistone IgG responses in a toll-like receptor (TLR)-2-
dependent manner, whereas nucleosomes from living cells did 
not. Thus, HMGB-1-nucleosome complexes activate antigen-
presenting cells and contribute to the pathogenesis of lupus via 
breaking the immunological tolerance against nucleosomes/
dsDNA.47 Furthermore, HMGB-1stimulates macrophages, 
monocytes, and neutrophils to release the proinflammatory 
cytokines TNF, IL-1, IL-6, IL-8, and macrophage inflamma-
tory protein-1. Thus, there is a close interaction between TNF, 
ILs, TLRs, and HMGB-1. Human microvascular endothelial 
cells are stimulated by HMGB-1 to increase their expression 
of ICAM-1, VCAM-1, TNF, and chemokines such as IL-8, 
suggesting that HMGB-1 can propagate the inflammatory 
response in the endothelium during infection and injury.
Anti-HMGB-1 antibodies protected mice against lethal 
endotoxemia in a dose-dependent fashion. Ethyl pyruvate 
(EP), stearoyl lysophosphatidylcholine, nicotine, and green 
tea extract significantly attenuated endotoxin-induced 
HMGB-1 release and protected animals from endotoxin-
induced lethal sepsis. Neutralizing antibodies against IFN-γ, a 
cytokine that is capable of stimulating HMGB-1 release, sig-
nificantly reduced circulating HMGB-1 levels in septic rats 
and protected animals from lethal sepsis.48 All the enumer-
ated actions of HMGB-1 suggest that it is a proinflammatory 
molecule and hence may have a role in lupus and RA.
It was reported that patients who developed autoantibod-
ies and/or lupus after treatment with procainamide or other 
drugs (drug-induced lupus) showed a high prevalence of 
antibodies to the nucleosomal core high-mobility-group pro-
teins such as HMGB-1.49 It was reported that the expression 
of HMGB-1 in the epidermis and dermis and an increase in 
the levels of TNF-α and IL-1β were reported in the dermal 
infiltrates of lesional skin. The high amount of extracel-
lular HMGB-1 observed in skin lesions in lupus indicates 
that HMGB-1 is involved in the inflammatory process of 
cutaneous lupus50 and, possibly, TNF-α and IL-1β may 
form a proinflammatory loop with HMGB-1, as they can 
induce the release of each other. In addition to HMGB-1, 
increased expression of TNF-α and IL-1β was noted in these 
dermal lesions, suggesting that extracellular and cytoplasmic 
HMGB-1 coincides with the clinically most active phase of 
cutaneous lupus.51 Because HMGB-1 can augment expres-
sion of TNF-α and IL-1β, and the latter can stimulate 
HMGB-1 formation, it is likely that a proinflammatory loop Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
152
Das
between HMGB-1, TNF-α, and IL-1β operates, which could 
be responsible for the prolonged and sustained inflammation 
in cutaneous lupus. These results, coupled with the observa-
tion that plasma levels of HMGB-1 are increased in patients 
with active lupus, indicate an active role for HMGB-1 in 
lupus and other rheumatological conditions.
Inflammatory and anti-inflammatory 
molecules and antioxidants in lupus
Thus, lupus, RA, and other rheumatological conditions are 
characterized by increased production of IL-1, IL-6, TNF-α, 
IFN-γ, MIF, HMGB-1, iNO, ROS, various chemokines, 
MPO, GM-CSF, G-CSF, endothelin, and hs-CRP.52–58 On the 
other hand, the concentrations of PGI2, PGE1, eNO, and anti-
oxidants such as superoxide dismutase (SOD) and glutathione 
peroxidase are decreased, whereas those of lipid peroxides 
are increased.52,59–61 It is likely that IL-1, IL-6, TNF-α, IFN-γ, 
HMGB-1, and MIF are released in large amounts in lupus 
and RA by activated neutrophils, macrophages, T-cells, 
synovial cells, fibroblasts, and endothelial cells not only 
to initiate the inflammatory process but also to perpetuate 
the inflammation.52 In addition, IL-1 increases the produc-
tion by endothelial cells of endothelin-1, which is a potent 
vasoconstrictor that could lead to Raynaud’s phenomena 
seen in lupus and other collagen vascular conditions such as 
scleroderma.62 Furthermore, IL-2 stimulates the production 
of autoantibodies and worsens immune-mediated diseases.63 
Cytokines including IL-6 and CSF-1 (colony stimulating 
factor-1) initiate immune response, induce cell prolifera-
tion, augment matrix-degrading protease activity, and cause 
resorption of bone (osteoporosis). Proteases released by 
activated neutrophils are responsible for bone erosions that 
are more common in RA than in lupus.
At the same time, certain anti-inflammatory molecules 
are produced that try to contain the inflammatory process 
and induce resolution of the disease process. For instance, 
TGF-β downregulates inflammation. Various cells, including 
monocytes, fibroblasts, platelets, and synovial tissue, produce 
it. TGF-β suppresses IL-1-stimulated collagenase transcrip-
tion (reviewed in Das52). TGF-β counters the degradation of 
cartilage induced by IL-1 and other cytokines,64 inhibits the 
growth of capillary endothelial cells, suppresses IL-1- and 
IL-2-dependent T-cell proliferation, inhibits free radical gen-
eration by human monocytes, and participates in wound heal-
ing and fracture repair.52 This suggests that TGF-β negatively 
regulates all the destructive and proinflammatory actions of 
IL-1, IL-2, TNF-α, HMGB-1, and MIF that are important 
to initiate the repair process and restore normalcy in lupus 
and other collagen vascular conditions. In contrast, excess 
production of TGF-β provokes and perpetuates fibroblast 
proliferation, leading to abnormal sclerosis in the skin and 
internal organs in scleroderma and in the kidney in lupus. 
This leads to late-stage complications in these conditions. 
Thus, TGF-β is a double-edged sword. When present in 
subnormal amounts, inflammation may go unchecked, and 
higher amounts may provoke abnormal sclerosis as seen in 
scleroderma.65 Hence, it is important to maintain normal 
amounts of TGF-β at a given site for normal physiology.
Immune dysfunction in lupus
Studies focused on cytokines and T-helper cells in the periph-
eral blood in patients with lupus have revealed inconsistent 
results that have led to confusion about the exact role of TH1 
and TH2 cells in lupus.66–70 In this context, it may be noted that 
activation of T-cells occurs at the site of disease involvement, 
and so peripheral plasma measurement of cytokines may not 
reflect the actual type of T-cells that are actively participating 
in the disease. In lupus, kidney biopsy is ideal in order to study 
intrarenal lymphocyte activation. Recently, measurement of 
messenger RNA (mRNA) expression in urinary sediment 
has been described,71 and it was shown that urinary mRNA 
and protein expressions of T-bet were significantly higher in 
lupus with active nephritis compared with those with inac-
tive disease. In contrast, the urinary and protein expressions 
of GATA-3 were significantly lower in lupus patients with 
active nephritis. Furthermore, tubular expressions of T-bet 
and GATA-3 significantly correlated with the histological 
activity index,72 suggesting that active lupus nephritis is 
associated with increased T-bet and decreased GATA-3 
expression in the urinary sediment and kidney tissue and indi-
cating a predominant TH1 type of T-lymphocyte activation. 
It is relevant to note that T-bet promotes TH1 lineage com-
mitment and forms an autoregulatory positive-feedback loop 
with IFN-γ to maintain a TH1-mediated immune response,73 
whereas GATA-3 promotes TH2 differentiation and induces 
TH2 cytokine production.74 Thus, the relative expression of 
T-bet and GATA-3, resulting in a swing in the TH1 and TH2 
expressions, would ultimately determine the type of T-helper 
cell expression. These results suggest that measurement of 
T-helper cell transcription factor gene expression is helpful 
in the assessment and risk stratification of lupus patients.
Loss of self-tolerance in lupus
In rheumatological conditions, the presence of diverse 
autoantibodies directed against a variety of intra- and 
extracellular components before the development of the Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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disease75 suggests that normal physiologic mechanisms 
that maintain tolerance to self-antigens have been breached. 
A subpopulation of T-cells known as Tregs establishes and 
preserves self-tolerance,76 and so the existence of defective 
helper and suppressor cells with defective signaling cas-
cades could result in autoantibody generation by forbidden 
B-cell clones and lead to impaired effector functions in 
lupus.77 These effector dysfunctions are a result of skewed 
expression of various effector molecules including CD40 
ligand (eg, CD154) and various cytokines and may reflect 
an imbalance of gene expression. Impaired effector T-cells’ 
function as a result of skewed cytokine production creates a 
microenvironment that facilitates a strong TH2 response rela-
tive to TH1 and Treg activity, which leads to overproduction 
of IL-4, IL-6, and IL-10 by TH2 and underproduction of IL-2, 
IL-12, TGF-β, and IFN-γ by TH1 and Tregs. That results 
in imbalanced autocrine and paracrine effects on T- and 
B-cells in the microenvironment. This imbalance in the 
cytokine production and reduced numbers of CD4+CD25+ 
Tregs results in insufficient suppressor activity in lupus, 
which results in dysregulated immune response driving both 
physiologic and forbidden B-cell clones to overproduce 
antibodies and autoantibodies. That results in hypergam-
maglobulinemia. These events occur despite the existence 
of other counter-regulatory mechanisms, including expres-
sion of the cell surface molecule cytotoxic T-lymphocyte 
antigen 4 (CTLA4).78 Studies with IL-2−/− and IL-2R−/− 
knockout mice revealed that IL-2 serves as a third signal 
that stimulates clonal expansion of effector cells to promote 
tolerogenic responses and to regulate development and 
function of CD4+CD25+ Tregs and CD8+ Tregs to maintain 
tolerance.79,80 It was noted that the frequency of CD4+CD25+ 
Tregs was significantly decreased in patients with active 
pediatric lupus compared with patients with inactive lupus 
and controls and was inversely correlated with disease activ-
ity and serum anti-dsDNA levels.81 Furthermore, an elevated 
surface expression of GITR in CD4+CD25+ T-cells, elevated 
mRNA expression of CTLA-4 in CD4+ T-cells, and higher 
amounts of mRNA expression for FOXP3 in CD4+ cells in 
patients with active lupus disease compared with patients 
with inactive disease and control were noted, indicating 
that a defective Treg population in pediatric lupus occurs 
and implying a role for FOXP3, CTLA-4, GITR, and CD4+ 
Tregs in the pathogenesis of lupus. These results are sup-
ported by the observation that a significant decrease in the 
suppressive function of CD4+CD25+ Tregs from peripheral 
blood of patients with active lupus occurs when compared 
with normal donors and patients with inactive lupus.82 
CD4+CD25+ Tregs isolated from patients with active lupus 
expressed reduced levels of FoxP3 mRNA and protein and 
poorly suppressed the proliferation and cytokine secretion of 
CD4+ effector T-cells in vitro. On the other hand, the expres-
sion of FoxP3 mRNA and protein and in vitro suppression of 
the proliferation of CD4+ effector T-cells by Tregs isolated 
from inactive lupus patients were comparable with that of 
normal individuals. In vitro activation of CD4+CD25+ Tregs 
from patients with active lupus increased FoxP3 mRNA and 
protein expression and restored their suppressive function, 
demonstrating that the defect in CD4+CD25+ Treg function 
in patients with active lupus is reversible. It was also noted 
that in newly admitted patients with the first manifesta-
tions of the disease and those treated with cytostatics and 
steroids, the coexpression of FoxP3 on CD4+CD25 T-cells 
was significantly reduced in both groups regardless of the 
therapy.83 The ability of Tregs to suppress proliferation of 
autologous CD8+ and CD4+ T-cells was significantly reduced 
in both groups of patients compared with healthy donors, 
though impaired production of Tregs in lupus patients could 
be partly restored by conventional treatments. These results 
imply that measurement of FoxP3 on CD4+CD25 T-cells and 
Tregs in lupus could form a marker of response to therapy 
and prognostic indicator and can be a new therapeutic 
strategy in lupus. It may be noted here that these results are 
not without controversy.84 Despite these controversies, it is 
likely that analysis of peripheral blood FOXP3+ T-cells may 
be useful for the evaluation of lupus disease activity.
It is reasonable to suggest that inflammatory responses 
of the immune system against several autoantigens seen in 
lupus are due to the continuous presence of autoantibodies 
and leaked autoantigens, eg, from not properly cleared dying 
and dead cells. Various soluble molecules and biophysical 
properties of the surface of apoptotic cells play significant 
roles in the appropriate recognition and further processing 
of dying and dead cells. It is important that an efficient 
clearance of dying cells in early and late phases of cell death 
is important to prevent activation of the immune response 
against self-antigens. The exposure of phosphatidylserine 
(PS) on the surface of apoptosing cells is recognized by 
several receptors and adaptor molecules for their clearance. 
Dying cells have cell membranes with high lateral mobil-
ity of PS, which contributes to their efficient clearance. 
Complement binding is an early event in necrosis and a late 
event in apoptosis. Complement, C-reactive protein (CRP) 
and serum DNase I act as backup molecules in the clearance 
process. Inappropriate accumulation of secondary necrotic 
cells and cellular debris in the germinal centers of secondary Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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lymph organs can lead to autoimmunity, and thus clearance 
defects are major players in the development of autoimmune 
diseases such as lupus.85,86
It is also important to note that high-dose cyclosporine 
(50 mg/kg cyclosporine) to pretransplant donor-specific 
blood transfusion abrogated Tregs generation, whereas a 
lower dose (10 mg/kg) of cyclosporine promoted Tregs 
development either in synergy with perioperative donor-
specific blood transfusion or by its own effect.87 These data 
suggest that, at times, a lower dose of cyclosporine is more 
beneficial in patients with lupus and RA aimed at inducing 
Tregs.
UV radiation-induced skin lesions  
in lupus and mast cells
The ability of UV radiation to suppress immune system is 
particularly interesting because understanding the molecular 
mechanisms of its action could pave the way to developing 
newer therapeutic strategies for immunological disorders. 
The beauty of immunosuppression induced by UV radiation 
lies in the fact that in contrast to conventional immunosup-
pression by immunosuppressive drugs, UV radiation does 
not compromise the immune system in a general fashion 
but rather in an antigen-specific fashion via induction of 
immunotolerance that is mostly mediated via regulatory 
T-cells (Treg). UV-induced Tregs express CD4+ and CD25+ 
and release upon activation the immunosuppressive cytokine 
IL-10 that suppresses immune responses in a general fashion 
called bystander suppression.88
On the other hand, the absence of immunosuppression 
to UV radiation in patients with lupus is rather puzzling, 
given its immunosuppressive nature. UV radiation-induced 
worsening of skin lesions in patients with lupus suggests not 
only that the responses of keratinocytes to UV radiation in 
lupus do not generate CD4+CD25+ Tregs that release IL-10 
to produce immunosuppression but also that in fact they may 
induce inflammation.
The paradoxical role of UV radiation in inducing immu-
nosuppression in normal but worsening skin lesions in lupus 
can be related to the interaction of UV radiation with mast 
cells.89 There is evidence to suggest that mast cells play an 
important role in the pathogenesis of lupus, RA, and other 
collagen vascular diseases.90 Recent evidence suggests that 
mast cells and their mediators, including LTs, play a signifi-
cant role in collagen vascular diseases.91 Several studies are 
in agreement with the concept that mast cells may contribute 
to the pathogenesis of connective tissue diseases scleroderma, 
vasculitic syndromes, and lupus.92,93 For example, inhibition 
of the growth factor receptor of human mast cells, c-Kit, 
by the selective tyrosine kinase inhibitor imatinib mesylate 
induces apoptosis of synovial tissue mast cells, and pre-
liminary findings suggest that inhibition of c-Kit could have 
antirheumatic activity.
Recent studies have suggested that keratinocyte apoptosis 
induced by ultraviolet-B radiation could be a potential source 
of fragmented autoantigens in lupus. The expression of Bcl-2, 
PCNA, p53, and Ki-67 proteins was studied by immuno-
histochemistry. In dermatomyositis and cutaneous lupus 
skin, the number of apoptotic keratinocytes was found to be 
significantly increased compared with normal skin. A large 
number of apoptotic keratinocytes expressed p53 protein; an 
increase in the number of proliferating Ki-67-positive and 
PCNA (proliferating cell nuclear antigen)-positive nuclei 
associated with exaggerated and inappropriate keratinocyte 
apoptosis was reported in these diseases compared with 
control. These results suggest that solar radiation induces 
DNA damage and excessive keratinocyte apoptosis in der-
matomyositis and cutaneous lupus that could be responsible 
for the epidermal lesions observed in both diseases.94 These 
results, coupled with the observation that in UVB-induced 
and lupus skin lesions in lupus patients there could be a defect 
in the removal of the apoptotic cells,95 suggest that humoral 
factors that play a significant role in inducing macrophages 
to clear cell debris such as LXs, resolvins, protectins, and 
maresins96 may play a significant role in skin lesions in 
autoimmune diseases.
Based on these data, it is likely that methods designed to 
enhance NO generation, enhance the number of Treg cells, 
block proinflammatory PG synthesis, stabilize mast cells, and 
enhance the synthesis and release of anti-inflammatory lipid 
mediators such as LXs, resolvins, protectins, and maresins 
could be of benefit in lupus and other collagen vascular dis-
eases. In this context, the role of PUFAs and their pro- and 
anti-inflammatory metabolites in inflammation appears to 
be important.
Pro- and anti-inflammatory lipids  
and their role in lupus
Inflammation is not a single event but a process in which 
cellular influx, persistence, and resolution of inflammation 
are controlled by several endogenous stop and go signals. It 
is evident from the discussion (see Metabolism of essential 
fatty acids) that products from AA, EPA, and DHA not only 
form precursors to various proinflammatory molecules such 
as PGE2, PGF2α, TXs, and LTs but also give rise to LXs and 
ATLs, resolvins, and protectins that are anti-inflammatory Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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in nature. For these pro- and anti-inflammatory compounds 
to form, initial activation of PLA2 that releases the precur-
sors from the cell membrane lipid pool is essential. Thus, 
there are two phases of release of PUFAs: one at onset 
of the generation of proinflammatory PGs, TXs, and LTs 
and one at the time of resolution for the synthesis of anti-
inflammatory LXs and ATLs, resolvins, and protectins.
There are three classes of phospholipases that control 
the release of AA and other PUFAs: calcium-independent 
PLA2 (iPLA2), secretory PLA2 (sPLA2), and cytosolic 
PLA2 (cPLA2).97 Each class of PLA2 is further divided into 
  isoenzymes: 10 for mammalian sPLA2, at least three for 
cPLA2, and two for iPLA2. During the early phase of inflam-
mation, COX-derived PGs and lipoxygenase-derived LTs 
  initiate exudate formation and inflammatory cell influx.8 
TNF-α causes an immediate influx of neutrophils concomi-
tant with PGE2 and LTB4 production, whereas during the 
phase of resolution of inflammation an increase in LXA4 
(lipoxin A4), PGD2, and its product 15deoxy∆12–14PGJ2 for-
mation occurs, which induces resolution of inflammation 
with a simultaneous decrease in PGE2 synthesis that stops 
neutrophil influx and enhances phagocytosis of debris.98,99 
Thus, there appears to be two waves of release of AA and 
other PUFAs: one at the onset of inflammation that causes the 
synthesis and release of PGE2, and a second at resolution for 
the synthesis of anti-inflammatory PGD2, 15deoxy∆12–14PGJ2, 
and LXs, which is necessary for the suppression of inflam-
mation. Thus, COX-2 enzyme has both harmful and useful 
actions by virtue of its ability to give rise to proinflammatory 
and anti-inflammatory PGs and LXs.
Increased type VI iPLA2 protein was found to be the 
principal isoform expressed from the onset of inflammation 
up to 24 h, whereas type IIa and V sPLA2 were expressed 
from the beginning of 48 h to 72 h. Type IV cPLA2 was not 
detectable during the early phase of acute inflammation but 
increased progressively during resolution, peaking at 72 h. 
This increase in type IV cPLA2 was mirrored by a parallel 
increase in COX-2 expression.100 The increase in cPLA2 and 
COX-2 occurred in parallel, suggesting a close enzymatic 
coupling between them. Thus, there is a clear-cut role for 
different types of PLA2 in distinct and different phases of 
inflammation. Selective inhibition of cPLA2 resulted in 
the reduction of proinflammatory molecules PGE2, LTB4, 
IL-1β, and PAF. Furthermore, inhibition of types IIa and V 
sPLA2 not only decreased PAF and LXA4 but also resulted 
in a reduction in cPLA2 and COX-2 activities. These results 
suggest that sPLA2-derived PAF and LXA4 induce COX-2 
and type IV cPLA2. IL-1β induced cPLA2 expression. This 
suggests that one of the functions of IL-1 is not only to induce 
inflammation but also to induce cPLA2 expression to initiate 
resolution of inflammation.101,102 Synthetic glucocorticoid 
dexamethasone inhibited both cPLA2 and sPLA2 expression, 
whereas type IV iPLA2 expression is refractory to its sup-
pressive actions.5,100,103 Activated iPLA2 contributes to the 
conversion of inactive proIL-1β to active IL-1β, which in 
turn induces cPLA2 expression that is necessary for resolu-
tion of inflammation. Both TNF-α and MIF might have a 
direct suppressive action on the synthesis of LXs, PGD2, 
and 15deoxy∆12–14PGJ2 from cPLA2-induced release of AA/
EPA/DHA. On the other hand, LXs, especially LXA4, inhibit 
TNF-α-induced production of ILs; promote TNF-α mRNA 
decay, TNF-α secretion, and leukocyte trafficking; and thus 
attenuate inflammation. This close interaction among PLA2s, 
COX-2, PGD2, LXA4, and PAF in the initiation, maintenance, 
and resolution of inflammation suggests that any imbal-
ance in this complex interplay during the various phases of 
inflammation could lead to either less optimal inflammation 
or persistence of inflammation.
Local levels of endogenous glucocorticoids appear to 
play a major role in the resolution of the inflammatory 
process. Corticosterone is released very early in the course 
of inflammation by stimulating the hypothalamic-pituitary-
adrenal axis by TNF-α, IL-1β, and IL-6, an event that is 
critical to the resolution of inflammation.104 It is known 
that iPLA2 is resistant to the inhibitory actions of dexam-
ethasone, whereas both cPLA2 and sPLA2 are inhibited. 
During the normal course of an inflammatory process, the 
local concentrations of endogenous corticosterone are high, 
whereas at the time of resolution they are low so that both 
cPLA2 and sPLA2 can be expressed to augment the produc-
tion of LXs, PGD2, and 15deoxy∆12–14PGJ2 to induce resolu-
tion of inflammation. Chronic use of corticosteroids would 
suppress sPLA2 and cPLA2 expression that is essential for 
the production of LXs, PGD2, and 15deoxy∆12–14PGJ2 to 
resolve inflammation, which explains why long-term use 
of steroids leads to nonhealing of inflammatory lesions 
and a flare-up of the inflammatory process when steroids 
are stopped.
It is interesting that iPLA2 enhances the conversion of 
pro-IL-1β to IL-1β by IL-converting enzyme.105 In contrast, 
high concentrations of cPLA2 suppress the conversion of 
pro-IL-1β to IL-1β. The formation of both LXA4 and PAF is 
maximal at the initiation of resolution of inflammation. Fur-
thermore, both LXA4 and PAF have the ability to upregulate 
COX-2 and cPLA2 expression, and COX-2 brings about 
the synthesis of PGD2 and 15deoxy∆12–14PGJ2, which have Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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anti-inflammatory actions. These results suggest that under 
normal physiological conditions, several lipid molecules act 
in a coordinated manner to resolve inflammation.
These findings suggest that both in RA and lupus, the flares 
and remissions are somewhat similar to onset and resolution 
of acute inflammatory process described above, in as much 
as the cell profile and mediators that initiate the response 
are similar. It is evident from the preceding discussion that 
COX-2 has an important role in resolving inflammation,19 
and hence the failure of NSAIDs to halt the progression of 
disease(s) could be due to the inhibition of COX-2.
Glucocorticoids and lipid  
mediators in inflammation
Corticosteroids are widely used in the treatment of vari-
ous inflammatory conditions. Although corticosteroids are 
effective anti-inflammatory compounds, they also have 
significant side effects. Glucocorticoids bring about their 
anti-inflammatory actions by 1) the induction and activation 
of annexin 1 (also called lipocortin-1),106 2) the induction of 
mitogen-activated protein kinase (MAPK) phosphatase 1,107 
and 3) the inhibition of COX-2108 and iNOS.109,110 Annexin-1 
or lipocortin-1 physically interacts with and inhibits cPLA2α so 
that AA is not released in adequate amounts to form precursors 
to various proinflammatory eicosanoids. Increased expres-
sion of cPLA2 is necessary to give rise to anti-inflammatory 
molecules PGD2 and 15deoxy∆12–14PGJ2, and LXs. Thus, 
the timing and quality and quantity of expression (perhaps a 
pulsatile expression) of cPLA2 and the local concentrations 
of glucocorticoids could be important factors that determine 
the progression and/or resolution of inflammation. Glucocorti-
coids also inhibit the production of proinflammatory cytokines 
such as IL-1, IL-6, TNF-α, and MIF.111–113 It is known that 
eNO activates constitutive COX-1, resulting in optimal release 
of PGE2, whereas iNO activates COX-2, resulting in markedly 
increased release of PGE2 and thereby inflammation.114 This 
implies that constitutive production of NO and PGE2 is anti-
inflammatory in nature, whereas inducible production of NO 
and PGE2 is proinflammatory, simply because the quantities of 
NO and PGE2 are extremely high in the latter instance. Low 
concentrations of glucocorticoids enhance MIF synthesis, 
which in turn overrides glucocorticoid-mediated inhibition of 
secretion of other proinflammatory cytokines. MIF induces 
the production of TNF-α and vice versa. Thus, there is a 
close interaction among glucocorticoids, MIF, TNF-α, NO, 
and eicosanoids (see Figure 9).
Glucocorticoids accelerated the catabolism of LTC4 
(leukotriene C4), a proinflammatory molecule;115 reduced 
PGD2, 15-HETE, LTB4, and TXB2; and enhanced 5-HETE 
and LTE4 (a less proinflammatory metabolite of LTC4)116 to 
dampen the inflammatory process. In addition, 15-HPETE 
and LXs, anti-inflammatory eicosanoids, cause a significant 
increase in the rate of TNF degradation.117 On the other hand, 
LXA4 not only inhibited the secretion of TNF-α118 but also 
prevented TNF-α-induced production of IL-1β, IL-6, cyclin 
E expression, and NF-κB activation.119 Thus, glucocorti-
coids and LXs have similar actions on   inflammation; both 
are anti-inflammatory, but their mechanisms of action seem 
to be different. It is relevant to note that both TNF-α and 
glucocorticoids have opposite actions on PLA2: the former 
stimulates120 while the latter inhibits.110 Thus, a close inter-
action exists among proinflammatory cytokines and lipid 
mediators of inflammatory and anti-inflammatory process 
and tissue repair (see Figure 10).
Because the amount and type of PUFA(s) released 
in response to inflammatory stimuli depend on the cell 
membrane phospholipid fatty acid content, it is reasonable 
to propose that dietary content PUFAs could be one fac-
tor that determines the degree of inflammation. Increased 
dietary intake of GLA, DGLA, and EPA/DHA substantially 
decreases inflammatory response121–126 as a result of decreased 
formation of proinflammatory eicosanoids and cytokines, 
and increases the production of beneficial eicosanoids such 
as PGE1, PGI2, PGI3, HPETEs, and eNO.19,127–132 It was noted 
that human embryonic kidney cells, in the presence of exog-
enous PUFAs (fatty acids that were used in this study were 
AA, LA, and oleic acid), on exposure to IL-1,   preferentially 
released AA due to the activation of sPLA2-IIA, type IV 
cPLA2, and type VI iPLA2. The degree of activation of these 
PLA2 was as follows: sPLA2-IIA . type IV cPLA2 . type 
VI iPLA2, indicating that exogenous PUFAs preferentially 
activate type IIA sPLA2-mediated AA release from IL-1-
stimulated cells. The order of release was AA . LA . oleic 
acid.133 This is interesting because it is evident from the 
preceding discussion that activation of cPLA2 and sPLA2 
would lead to the formation of anti-inflammatory LXs, PGD2, 
and 15deoxy∆12–14PGJ2, lending support to the hypothesis 
that lipid composition of the cell membrane can potentially 
modulate response to inflammation.
It is also reasonable to suggest that failure to generate ade-
quate amounts of LXs and resolvins could lead to persistence 
of inflammation as seen in RA, lupus, glomerulonephritis, and 
other conditions that could be due to continued synthesis and 
secretion of inflammatory cytokines IL-1, IL-2, IL-6, IL-8, 
TNF-α, and MIF. On the other hand, IFN-γ and IL-13 could 
trigger production of LXs and resolvins such that resolution of Journal of Inflammation Research 2010:3
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Figure 9 Scheme showing possible interaction between PUFAs (AA, ePA, and DHA), their products such as PGs, LTs, TXs, LXs, resolvins, protectins, and maresins, and TH1 
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inflammation is initiated. When this delicate balance between 
pro- and anti-inflammatory cytokines and PGs and LXs and 
resolvins is dysregulated, it will lead to persistence of inflam-
mation (see Figure 10). It is possible that the balance (or ratio) 
between the concentrations of AA, EPA, and DHA in the cell 
membrane could be one factor that determines the amount of 
LXs, resolvins, PGD2, and 15deoxy∆12–14PGJ2 formed.
Nitric oxide, lipid peroxides,  
and antioxidant status in lupus
Serum nitrite levels were reported to be significantly elevated 
in patients with lupus (mean ± SEM = 37 ± 6 µM/L) compared 
with controls (15 ± µM/L; P , 0.01), and were elevated in 
patients with active lupus compared with those with   inactive 
disease (46 ± 7 versus 30 ± 7 µM/L; P , 0.01), and serum 
nitrite levels correlated with disease activity and with levels 
of antibodies to dsDNA. Endothelial cell expression of iNOS 
in lupus patients was significantly greater compared with 
controls, and higher in patients with active disease compared 
with those with inactive lupus. Even keratinocyte expression 
of iNOS was significantly elevated in lupus compared with 
controls, whereas eNOS activity was similar in patients with 
active lupus and inactive lupus and normal controls in either 
the vascular endothelium or the keratinocytes.134 These and 
other results suggest that iNO production is enhanced in active 
lupus, including neuropsychiatric lupus,135–137 which could be 
responsible for vascular and cutaneous inflammation seen 
in these patients. Similar results have been reported in IgA 
nephropathy and lupus nephropathy,138–140 and the beneficial 
effect of the immunosuppressive drug mycophenolate mofetil Journal of Inflammation Research 2010:3
Figure 10 Scheme showing the role of prostaglandins and lipoxins in inflammation and its resolution. (−) indicates inhibition or suppression of action; (+) indicates activation 
or enhancement of action. For further details see text.
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and anti-inflammatory compound PGJ2 has been attributed 
to their ability to suppress iNOS.139,140
1,25-Dihydroxyvitamin  
D3 suppresses autoimmunity
The active form of vitamin D3, 1-α,25-dihydroxyvitamin 
D3 (1,25-vitamin D3), suppresses in vitro immunoglobulin 
production and inhibits IL-2 production by activated blood 
mononuclear cells (PBM) by specifically targeting TH lym-
phocytes.141 In addition, 1,25-vitamin D3 not only inhibited 
IL-12-generated IFN-γ production but also suppressed IL-4 
and IL-13 expression induced by IL-4.142 It also prevented 
partly reversed experimental autoimmune uveitis (EAU) 
disease by suppressing immunological responses by directly 
suppressing IL-17 induction in purified naive CD4(+) 
T-cells.143 Thus, 1,25-dihydroxyvitamin D3 appears to sup-
press autoimmunity by inhibiting the Th-17 response. This 
evidence suggests that 1,25-dihydroxyvitamin D3 may be 
useful in suppressing disease activity in patients with lupus, 
RA, and other rheumatological conditions.52
ADMA in rheumatological conditions
Plasma eNO levels are low in patients with lupus and 
RA,52,60,61 which could trigger vasospasm and cause 
  Raynaud’s phenomenon seen in rheumatological conditions. 
These low NO levels could be due to 1) substrate deficiency, 
2) low activity of the eNOS enzyme, and 3) rapid inactiva-
tion of eNO.
Arginase and NO synthase (NOS) compete for the 
same substrate, l-arginine, and the reciprocal regulation 
of arginase and NOS in l-arginine-metabolizing pathways 
is known. Both serum arginase activity and protein levels Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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were significantly higher in patients with RA compared with 
healthy controls. A significant correlation between the serum 
concentrations of arginase protein and rheumatoid factor 
was also noted in RA patients, suggesting that increased 
arginase production may be responsible for low l-arginine 
levels and eNO formation.144
Asymmetric dimethylarginine (ADMA), an endogenous 
NO synthesis inhibitor, is an independent risk factor for 
endothelial dysfunction and cardiovascular disease. Mean 
plasma ADMA levels were significantly higher in patients 
with lupus with a history of cardiovascular episodes than in 
patients without such a history, and high SLEDAI (SLE dis-
ease activity index) score, high titer of anti-dsDNA antibod-
ies, and low serum HDL were significantly associated with 
high plasma ADMA levels. These results suggest that patients 
with lupus are at high risk of developing cardiovascular 
diseases due to high plasma ADMA levels.145 In addition, it 
was reported that TNF-α levels and other indices that reflect 
endothelial damage, such as sVCAM-1, were found to be 
elevated in lupus and other rheumatological conditions.146,147 
Further support to the role of NO in rheumatological condi-
tions is derived from previous studies where it was observed 
that drug-resistant Raynaud’s phenomenon in lupus responds 
to oral l-arginine therapy.148 That could be attributed to an 
increase in the generation of NO. These results are supported 
by the work of Fries et al,149 who showed that sildenafil, the 
NO donor, is of benefit in the management of Raynaud’s 
phenomenon.
Increased production of IL-1, IL-6, TNF-α, IFN-γ, 
MIF, and HMGB-1 attracts neutrophils, macrophages, and 
T-cells to initiate and perpetuate the inflammatory process 
by increasing the production of free radicals, eicosanoids, 
and cytokines in an autocrine fashion.1 IL-1 increases the 
production of endothelin-1 in cultured endothelial cells,150 
and this contributes to vasospasm seen in lupus. Endothelial 
cells also produce PGI2 and NO, which are potent vasodila-
tors and platelet antiaggregators and natural antagonists of 
endothelin-1. Hence, enhancing the production of NO and/
or decreasing endothelin-1 and suppressing the production of 
proinflammatory molecules and enhancing the synthesis of 
anti-inflammatory molecules could be of significant benefit 
in lupus and other rheumatological conditions.
In this context, it is interesting to note that recent stud-
ies have led to the identification of several newer methods 
of suppressing inappropriate generation of free radicals 
and proinflammatory cytokines, enhancing resolution of 
inflammation, and restoring immune balance and organ 
dysfunction to normal. Some of these strategies include 
immunosuppressive drugs such as FK-506, B-cell-targeted 
therapies, complement-component-targeted therapies, use 
of monoclonal antibodies against IFN-α, glucose–insulin 
infusion, administration of EP, lipid-enriched albumin, vagal 
nerve stimulation, and use of endogenous anti-inflammatory 
lipids such as LXs, resolvins, protectins, or their synthetic 
analogs along with their precursor PUFAs in combination 
with aspirin. These newer methods could be adopted in addi-
tion to the existing therapeutic modalities. A brief summary 
of these proposed newer therapeutic strategies is outlined 
below.
FK-506
Tacrolimus (also FK-506 or Fujimycin) is an immunosup-
pressive drug that is mainly used after allogeneic organ 
transplant to reduce the activity of the immune system, 
thereby lowering the risk of organ rejection. It reduces IL-2 
production by T-cells. It is also used in a topical prepara-
tion in the treatment of severe atopic dermatitis (eczema), 
severe refractory uveitis after bone marrow transplanta-
tion, and the skin condition vitiligo. It is a 23-membered 
macrolide lactone derived from the bacteria Streptomyces 
tsukubaensis.
In T-cells, activation of the T-cell receptor increases 
intracellular calcium, which acts via calmodulin to activate 
calcineurin. That dephosphorylates the transcription factor 
NF-AT (nuclear factor of activated T-cells), which moves 
to the nucleus of the T-cell and increases the activity of 
gene coding for IL-2 and related cytokines. Tacrolimus 
prevents the dephosphorylation of NF-AT. Tacrolimus 
reduces peptidylprolyl isomerase activity by binding to 
the immunophilin FKBP12 (FK-506 binding protein), 
forming FKBP12-FK-506 complex, which interacts with 
and inhibits calcineurin, thus inhibiting both T-lymphocyte 
signal transduction and IL-2 transcription.151 Although this 
activity is similar to cyclosporin, studies have shown that 
the incidence of acute rejection is reduced by tacrolimus 
use over cyclosporin. Although short-term immunosuppres-
sion concerning patient and graft survival is found to be 
similar between the two drugs, tacrolimus results in a more 
favorable lipid profile. This may have important long-term 
implications, given the prognostic influence of rejection on 
graft survival.
In a study involving patients with end-stage renal disease 
secondary to lupus who received kidney transplantation, the 
actuarial patient and graft survivals at 5 years were noted to be 
100% and 93%, respectively, in those who received calcineu-
rin-based immunosuppression (cyclosporine or tacrolimus). Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Recurrence of clinical or serological disease of lupus was 
never detected. This favorable response observed in these 
patients of lupus suggested that tacrolimus or cyclosporine 
at low doses is effective in preventing lupus reactivation.152 
Several recent studies have confirmed the beneficial actions 
of tacrolimus or FK-506, especially in the management of 
lupus nephritis.153,154
B-cell-targeted therapies for lupus
Rituximab is a chimeric monoclonal antibody against the 
protein CD20, which is primarily found on the surface of 
B-cells. It can therefore destroy B-cells. Rituximab is used in 
the treatment of many lymphomas and leukemias, to suppress 
transplant rejection and autoimmune disorders.
There are increasing data from open-label studies to 
suggest that B-cell depletion using rituximab is useful in the 
treatment of lupus.155 However, larger double-blind clinical 
trials to confirm this belief are awaited. Rituximab has been 
shown to be an effective RA treatment in three randomized 
controlled trials and is now licensed for use in refractory rheu-
matoid disease.156 In the United States, it has been approved 
for use in combination with methotrexate for reducing signs 
and symptoms in adult patients with moderately to severely 
active RA who have had an inadequate response to one or 
more anti-TNF-α therapies. There is some evidence for 
efficacy, but not necessarily safety, and rituximab is widely 
used off-label to treat lupus. There are significant concerns 
about progressive multifocal leukoencephalopathy (PML) 
infection in lupus.
Another B-cell-targeted therapeutic approach is to 
block costimulatory interactions between T- and B-cells. 
Blockade of the CD40–CD40 ligand pathway has met with 
variable clinical benefit and unfortunate thromboembolic 
complications, although inhibition of the B7 pathway with 
cytotoxic T-lymphocyte antigen-4Ig is currently under early 
investigation in lupus clinical trials. In a phase II, double-
blind, placebo-controlled trial of the safety and efficacy 
of three different doses administered in addition to standard 
therapy, belimumab, a fully human monoclonal antibody 
that specifically binds to and neutralizes the B-lymphocyte 
stimulator (BLyS or B-cell-activating factor (BAFF)), was 
well tolerated but reportedly did not meet primary efficacy 
endpoints.157 Blockade of BAFF is still viewed as a promis-
ing therapeutic approach, and additional agents that interfere 
with the BAFF pathway are under study. Overall, therapies 
targeting B-cells appear to be promising in the treatment of 
lupus, but more convincing data need to be obtained before 
their approval for use in the clinic.158
Complement-component-targeted 
therapy for lupus
Two members of the pentraxin family of proteins, CRP and 
serum amyloid P component (SAP), bind to chromatin and 
are involved in the solubilization and clearance of nuclear 
material. It is known that CRP binding to chromatin is medi-
ated by histones. SAP differs from CRP in being able to bind 
to DNA. CRP is an activator of the classical complement 
pathway, and complement-dependent cleavage of chromatin 
in the presence of CRP and serum is known to occur. Oligom-
ers of SAP have been found to bind to C1q and consume total 
C and C4, indicating that SAP can activate complement as 
well. SAP binding to histones H1 and H2A was observed as 
well as SAP binding to chromatin. In contrast to CRP, SAP 
binding to chromatin did not require H1. SAP partially inhib-
ited CRP binding to chromatin and to H1. Binding of either 
CRP or SAP to H2A activated complement in SAP-depleted 
serum, leading to the deposition of C4 and C3. Complement 
activation required C1q and produced C4d, indicating that it 
occurred through the classical pathway and suggesting that 
CRP and SAP share histone as well as chromatin binding 
and that both pentraxins can activate the classical C pathway 
after ligand binding.159
SAP shows specific calcium-dependent binding to DNA 
and chromatin in physiological conditions. The avid binding 
of SAP displaces H1-type histones and thereby solubilizes 
native long chromatin, which is otherwise profoundly 
insoluble at the physiological ionic strength of extracellular 
fluids. SAP binds in vivo to apoptotic cells, the surface 
blebs of which bear chromatin fragments, and to nuclear 
debris released by necrosis. SAP may therefore participate 
in handling of chromatin exposed by cell death. Mice with 
targeted deletion of the SAP gene spontaneously develop 
antinuclear autoimmunity and severe glomerulonephritis, a 
phenotype resembling human lupus. The SAP−/− mice also 
have enhanced anti-DNA responses to immunization with 
extrinsic chromatin, and degradation of long chromatin is 
retarded in the presence of SAP both in vitro and in vivo, 
suggesting that SAP has an important physiological role 
of inhibiting the formation of pathogenic autoantibodies 
against chromatin and DNA, probably by binding to chro-
matin and regulating its degradation.160,161 This is supported 
by the observation that the measurement of antichromatin, 
but not anti-C1q, antibodies in patients with lupus increases 
diagnostic sensitivity and specificity for lupus and assists 
in treatment decisions in anti-dsDNA-negative patients.162 
However, the role of SAP in the development of autoimmune 
diseases has been disputed.163Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Nevertheless, it is useful to measure serum levels of 
CH50, C3, and C4 in patients with immune-mediated dis-
eases. Recent studies have demonstrated that the defect in 
the clearance of immune complexes and apoptotic cells is 
associated with autoimmune disease. Mice deficient in Clq 
show a lupus-like phenotype with the appearance of anti-
nuclear antibodies and glomerulonephritis due to a defect 
in the clearance of immune complexes and apoptotic cells. 
This at least explains the paradox that, in humans, deficiency 
in an early complement component is a major risk factor for 
lupus. Because the complement system is a central mediator 
of inflammation, it is considered as a promising therapeutic 
target. Anti-C5 monoclonal antibody blocks the final stage of 
complement activation. Pexelizumab is a single-chain, short-
acting, anti-C5 antibody and is used for reperfusion after 
myocardial infarction, or for coronary artery bypass graft 
surgery with cardiopulmonary bypass, whereas eculizumab 
is a long-acting, anti-C5 antibody used for paroxysmal noc-
turnal hemoglobinuria, rheumatoid arthritis, and membranous 
glomerulonephritis with promising results.164,165
Monoclonal antibodies against IFN-α
The immunoregulator human γ-interferon (IFN-γ) suppressed 
the spontaneous in vitro synthesis and secretion of anti-
DNA antibodies by peripheral blood mononuclear cells of 
patients with lupus. Comparable levels of suppression were 
observed with both natural human IFN-γ and recombinant 
derived human IFN-γ, and the inhibitory effects of human 
IFN-γ could be completely neutralized by a monoclonal 
antibody directed against it. Human IFN-γ also inhibited 
the antigen-induced production of anti-DNA synthesis by 
peripheral blood mononuclear cells of patients with lupus, 
probably by acting directly on the B-cell. Furthermore, 
human IFN-γ suppressed the spontaneous production of IgG 
and IgM by peripheral blood mononuclear cells of patients 
with lupus.166 These findings support the possibility that 
immunoglobulin production in lupus can be regulated and 
that human IFN-γ could be useful in the treatment of lupus 
and other immune complex diseases. However, this optimism 
was short-lived.167
Subsequent studies showed that patients with lupus 
have an increased expression of type I IFN-regulated 
genes because of a continuous production of IFN-α. 
Plasmacytoid dendritic cells (pDCs) activated by immune 
complexes containing nucleic acids secrete type I IFN in 
lupus. Type I IFN causes differentiation of monocytes to 
myeloid-derived dendritic cell (mDC) and activation of 
autoreactive T- and B-cells. Therefore, it is argued that 
inhibition of IFN-α could be useful in the management 
of lupus. Recent data from a phase I clinical trial suggest 
that administration of neutralizing monoclonal antibod-
ies against anti-IFN-α can ameliorate disease activity.168 
However, more clinical data are necessary before the use 
of neutralizing monoclonal antibodies against anti-IFN-α 
comes into clinical practice.
Proresolution of inflammation, repair,  
and wound healing induction  
as a therapeutic strategy for lupus  
and other autoimmune diseases
It is evident from the preceding discussion that current 
therapeutic approaches have been directed to suppress 
inflammation and immune response as their major objec-
tives in the management of lupus and other autoimmune 
disorders. Although these strategies have been reasonably 
successful, they are associated with many side effects, 
and induction of disease remission has not been truly suc-
cessful. The current therapeutic approaches are associated 
with many side effects, such as susceptibility to infec-
tions, development of hypertension and diabetes mellitus 
(especially with corticosteroids and cyclosporine), the 
unpredictable nature of remission, and recurrences of the 
underlying disease and in the long-term development of 
malignancies. These unwarranted side effects suggest that 
more robust and reliable and, perhaps, novel therapeutic 
approaches are needed in the management of lupus and 
other autoimmune diseases. Until now, relatively little 
attention has been paid to the resolution and repair phase 
of inflammation and to exploiting these mechanisms to 
devise newer therapeutic approaches to lupus. The natural 
process of resolution of inflammation and wound healing 
is successfully implemented by our body to allow many 
patients to recover completely from inflammation induced 
by infections, injury, and surgery. Such a natural process 
of resolution and wound repair has the capability to restore 
tissue architecture and function to normal. Hence, I propose 
that newer therapeutic strategies to manage lupus and other 
autoimmune diseases could be based on the principles of 
enhancing natural process(s) of resolution of   inflammation, 
wound healing, and repair, so that relatively few side 
effects are likely to occur. Such a natural process of reso-
lution and repair could depend on a better understanding 
of the normal physiology of wound healing as discussed 
previously. Some of the endogenous molecules involved 
in such resolution of inflammation, wound healing, and 
repair are discussed below.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Glucose–insulin–potassium regimen
A glucose–insulin–potassium (GIK) regimen is used to treat 
patients with a moderate degree of hyperglycemia, even in 
the absence of ketoacidosis, and those with diabetic ketoaci-
dosis. Satomi et al169 showed that glucose administration 
and insulin injections to presensitized mice inhibited TNF 
production. Fraker et al170 reported that recombinant human 
TNF-cachectin-induced decrease in food intake, nitrogen bal-
ance, and body weight gain compared with saline controls in 
rats can be reversed by concurrent administration of insulin 
without causing any treatment deaths. Further, 5 days of TNF-
cachectin treatment induced severe interstitial pneumonitis 
and periportal inflammation in the liver, and an increase in 
wet organ weight in the heart, lungs, kidney, and spleen in the 
rats could be reverted to normal when insulin treatment was 
given concurrently. These results suggest that administration 
of insulin reverses the nutritional and histopathologic toxic-
ity of sublethal doses of TNF. Ottlecz et al171–173 showed that 
insulin may have anti-inflammatory action against carrageen-
an-induced paw edema. Boichot et al174 demonstrated that 
luminol-dependent chemiluminescence by the mononuclear 
cells in the bronchoalveolar lavage (BAL) fluid and the levels 
of TNF-α in the BAL supernatant reverted to normal levels 
after treatment of Wistar diabetic rats with insulin, indicating 
that insulin regulates superoxide anion generation and TNF-α 
synthesis and release, and thus may have anti-inflammatory 
action.170–175 Insulin enhances the expression of the eNOS 
gene both in vitro and in vivo.176 Because NO can quench the 
superoxide anion,177 this may be of benefit in inflammatory 
conditions. Furthermore, the expression of MIF in adipocytes 
can be modulated by insulin and glucose.178 MIF is secreted 
together with insulin from pancreatic β cells and acts as an 
autocrine factor to stimulate insulin release.179 During the 
systemic inflammatory process, including RA and lupus, 
MIF is secreted from the pituitary gland, accompanied by an 
increase in glucocorticoid secretion. The increase in plasma 
glucose levels that occurs as a result of this glucocorticoid 
secretion is probably controlled by MIF by its positive effect 
on insulin secretion. TNF-α upregulates MIF secretion.180 On 
the other hand, TNF-α induces insulin resistance.181 Thus, 
glucose homeostasis during systemic inflammatory process 
is regulated by glucocorticoids, TNF-α, MIF, and insulin. 
In view of the feedback control among MIF, glucose, and 
insulin, it is likely that infusion of glucose and insulin inhibits 
MIF production and release similar to their inhibitory action 
on TNF-α.182–184 In support of this postulation, we recently 
showed that insulin inhibited ischemia/reperfusion-induced 
TNF-α and MPO (myeloperoxidase) production through 
the Akt-activated and eNOS-NO-dependent pathway in 
cardiomyocytes. Thus, insulin has potent anti-inflammatory 
properties that may contribute to its cardioprotective and 
cytoprotective actions. That explains its prosurvival effects 
in the critically ill.185 In view of this, it will be interesting to 
use GIK regimen in the management of patients with lupus, 
RA, and other rheumatological conditions. Perhaps it is 
worthwhile to administer insulin (without inducing hypo-
glycemia) twice or three times daily and monitor the clinical 
manifestations and plasma IL-6, TNF-α, MIF, and NO levels 
in these patients. For those who are critically ill with lupus 
and RA, it may be interesting to administer a GIK regimen 
in a hospital setting and monitor their response.
ethyl pyruvate
Pyruvic acid is present in the cells and extracellular fluids as 
its conjugate anion, pyruvate. Pyruvic acid, being the final 
product of glycolysis and the starting substrate for the tricar-
boxylic acid (TCA) cycle, plays a crucial role in intermediary 
metabolism. Pyruvate is unstable in solutions, and spontane-
ously undergoes condensation and   cyclization. EP, a deriva-
tive of pyruvic acid, in a calcium- and potassium-  containing 
balanced salt solution (called a Ringer EP solution) is not only 
stable and nontoxic but a more effective anti-  inflammatory 
molecule than pyruvate.186 EP is extensively used and 
approved by the Food and Drug Administration (FDA) as 
a food additive. EP is used in a calcium-containing solu-
tion because it is a hydrophilic compound. The calcium 
prevents emulsion and increases the solubility. Because EP 
is chemically related to lactate, substituting lactate for EP 
can provide a therapeutic anti-inflammatory property to the 
Ringer’s solution. EP, derived from ethanol and pyruvic 
acid, in a Ringer-type Ca2+- and K+-containing balanced 
salt solution is not only stable but also more effective than 
sodium pyruvate.187
Ringer EP solution prolonged survival of rats that were 
in hemorrhagic shock186,187 by effectively scavenging the free 
radicals.188–190 In vitro studies showed that EP inhibited the 
release of TNF-α and HMGB-1 from endotoxin-stimulated 
murine macrophages and attenuated activation of NF-κB sig-
naling pathways. In an LPS-induced endotoxic shock animal 
model, EP improved survival by lowering circulating con-
centrations of nitrite/nitrate (metabolites of NO) and IL-6, 
which are proinflammatory molecules, and enhanced plasma 
levels of IL-10, an anti-inflammatory cytokine,191 suggesting 
that EP has significant anti-inflammatory actions.
In view of these significant anti-inflammatory actions,192–194 
it is anticipated that administration of EP may be of use in Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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suppressing inflammatory events in lupus, RA, and other 
rheumatological conditions.
Lipid-enriched albumin
Albumin, the major protein produced by hepatocytes in the 
liver, maintains oncostatic pressure. Albumin traps oxygen rad-
ical and quenches free radicals, inhibits copper-ion-dependent 
lipid peroxidation, and retards the formation of hydroxyl 
  radicals, and thus exhibits both neuroprotective and cytopro-
tective actions. This beneficial action of albumin is due to its 
ability to mobilize DHA and possibly other PUFAs from liver 
and other tissue that, in turn, are converted to anti-inflamma-
tory molecules such as protectins, LXs, and resolvins.
On administration of albumin-DHA complex containing 
2.1 ± 0.1 µM DHA/mL of albumin to the 2 h middle cerebral 
artery suture-occlusion animal model, high-degree neu-
robehavioral and histological neuroprotection was noted.195 
  Albumin-DHA complex facilitates DHA delivery to the brain 
so that significant amounts of NPD1 could be formed to prevent 
ischemia-reperfusion injury. DHA confers neuroprotection by 
opening background K+ channels and inhibiting apoptosis. 
Administration of albumin-DHA complex increased the 
formation of NPD1 and infusion of NPD1; reduced infarct 
size; and diminished PMNL infiltration, NF-κB activation, 
and proinflammatory COX-2 expression.21,196 In view of these 
anti-inflammatory actions, it is possible that albumin-PUFA 
complexes could be of significant benefit in the management 
of rheumatological conditions RA and lupus.
vagal nerve stimulation suppresses 
inflammation
CNS regulates the production of proinflammatory cytokines, 
such as TNF, IL-1, HMGB-1, IL-6, and MIF, through the 
efferent vagus nerve.197–199 Acetylcholine, the principal vagus 
neurotransmitter, inhibits the production of proinflammatory 
cytokines through a mechanism dependent on the α7 nicotinic 
acetylcholine receptor subunit. Thus, vagus nerve stimulation 
(VNS) controls the production of proinflammatory cytokines. 
Strong expression of a7nAChR in the synovium of RA and 
psoriatic arthritis patients was detected.200 Both peripheral mac-
rophages and synovial fibroblasts have been shown to respond 
in vitro to specific a7nAChR cholinergic stimulation with potent 
inhibition of proinflammatory cytokines.197–199 It is likely that 
fibroblasts, especially in the lining layer, may have the ability 
to balance inflammatory mechanisms and arthritis development 
through feedback cholinergic stimulation by nearby immune 
cells. It is possible that specific cholinergic mechanisms may 
also be involved in regulation of antibody production locally in 
the joint. This implies that new therapies directed at regulation 
of the cholinergic and a7nAChR-mediated mechanisms in the 
management of lupus and RA could be developed.
This proposal is supported by the recent observation 
that measurement of RR interval variability (heart rate 
variability, HRV) as a marker of vagus nerve tone (which 
reflects parasympathetic activity) in RA patients revealed 
that vagus nerve activity was significantly depressed in 
patients compared with control.201 These findings suggest 
that it is possible to pharmacologically target the a7nAChR-
dependent control of cytokine release in RA patients with 
suppressed vagus nerve activity. As a7nAChR agonists 
ameliorate the clinical course of collagen-induced arthritis 
in animals, it may be possible to explore whether a7nAChR 
agonists can improve clinical activity in RA patients. Fur-
thermore, it was reported that collagen-induced arthritis 
in a7nAChR(–/–) mice was significantly severe and showed 
increased synovial inflammation and joint destruction com-
pared with the wildtype mice. Exacerbation of the arthritis 
was associated with elevated systemic proinflammatory 
cytokines and enhanced T-helper cell 1 (Th1)-cytokine and 
TNF-α production by spleen cells. These results indicate 
that immune cell function in a model of RA is regulated by 
the cholinergic system and, at least in part, mediated by the 
a7nAChR.202 The clinical implications of these findings are 
that VNS could be employed in the treatment of lupus, RA, 
and other autoimmune diseases.
VNS is currently in use as an adjunctive treatment for 
certain types of intractable epilepsy and major   depression.203 
VNS uses an implanted stimulator that sends electric impulses 
to the left vagus nerve in the neck via a lead wire implanted 
under the skin. VNS implantation devices consist of a titani-
um-encased generator about the size of a pocket watch with a 
lithium battery to fuel the generator, a lead wire system with 
electrodes, and an anchor tether to secure leads to the vagus 
nerve. The battery life for the pulse generator is between 1 
and 16 years, depending on the settings, ie, how strong the 
signal being sent is, the length of time the device stimulates 
the nerve each time, and how frequently the device stimulates 
the nerve. Implantation of the VNS device is usually done as 
an outpatient procedure. Because the VNS device is already 
in use and is relatively safe, this could be tried for the man-
agement of lupus and other autoimmune diseases.
Lipoxins, resolvins, protectins,  
or their synthetic analogs
As discussed previously, LXs, resolvins, and protectins are 
potent endogenous anti-inflammatory compounds whose Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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deficiency could lead to unabated inflammation. Hence, 
methods designed to enhance their formation, such as coad-
ministration of aspirin with PUFAs and/or development and 
use of their stable synthetic analogs, may prove to be useful 
in various rheumatological conditions. Such an approach is 
urgently needed.
Ghrelin
Ghrelin is a growth hormone secretagogue produced by the 
gut and is expressed in the hypothalamus and other tissues 
as well. Ghrelin not only plays an important role in the regu-
lation of appetite, energy balance, and glucose homeostasis 
but also shows antibacterial activity, suppresses proinflam-
matory cytokine production, and restores gut barrier func-
tion. Ghrelin inhibits proinflammatory cytokine production, 
mononuclear cell binding, and nuclear factor-κB activation 
in human endothelial cells in vitro and endotoxin-induced 
cytokine production in vivo.204 Ghrelin stimulates the vagus 
nerve. Experimental studies revealed that vagotomy pre-
vented ghrelin’s downregulatory effect on TNF-α and IL-6 
production, confirming that ghrelin downregulates proin-
flammatory cytokines in sepsis through activation of the 
vagus nerve.205 Ghrelin has sympathoinhibitory properties 
that are mediated by central ghrelin receptors involving a 
NPY/Y1-receptor-dependent pathway.206 Ghrelin inhibited 
the production of HMGB-1 by activated macrophages,207 
which may explain its beneficial action in sepsis and other 
inflammatory conditions.208,209 These results suggest that 
ghrelin infusion could be of significant benefit in lupus, RA, 
and other autoimmune diseases not only by its direct action 
of the production of proinflammatory cytokines but also 
by its ability to stimulate vagus that has anti-inflammatory 
actions.
Conclusion
Lupus, RA, and other autoimmune diseases are chronic 
inflammatory conditions that often have acute and intermit-
tent inflammatory episodes. More often than not, these are 
lifelong diseases and are associated with considerable renal, 
pulmonary, and cardiac complications that could lead to 
death. Current therapeutic approaches depend on the use 
of synthetic and potent anti-inflammatory and immunosup-
pressive drugs that are often associated with significant side 
effects. Some of the current drugs in use include nonsteroidal 
anti-inflammatory compounds, chloroquine (hydroxychloro-
quine), corticosteroids (oral or parenteral), d-penicillamine, 
sulfasalazine, methotrexate, anti-TNF antibodies (treat-
ment with anti-TNF monoclonal antibodies, infliximab, 
adalimumab, and certolizumab pegol has been shown to 
provide substantial benefit to patients of RA, Crohn’s disease, 
and psoriasis through reductions in both localized and sys-
temic expression of markers associated with inflammation), 
Table 1 Response and/or prognosis of lupus, RA, and other rheumatological conditions can be assessed biochemically by measuring 
the various indices mentioned below. These indices need to be measured/assessed in addition to clinical features while employing 
various therapeutic approaches
Biochemical/immunological test Significance/comments
Plasma insulin Insulin resistance is likely in lupus and RA. Insulin has anti-inflammatory  
actions
Plasma hs-CRP, IL-6, TNF-α, MIF, HMGB-1, IL-1, IL-2,  
ICAM-1, vCAM-1, PeCAM, IFN-γ, IL-17, IL-18, IL-12, PAF
Marker of inflammation and disease activity
IL-4, IL-10, IL-27, TGF-β These are anti-inflammatory cytokines, and their increase suggests a decrease in 
the activity of the disease and possible impending remission
Plasma AA, ePA, DHA, lipoxins, resolvins, protectins,  
maresins, nitrolipids
These are anti-inflammatory lipid molecules; their measurement prior to disease 
and after institution of therapy may indicate remission or progression of disease. 
Their increase suggests a decrease or resolution of inflammation
Plasma ADMA Inhibits eNO, and its levels are increased in CHD, metabolic syndrome, and 
rheumatological conditions
Plasma pyruvate Pyruvate is an antioxidant and suppresses IL-6, TNF-α, and MIF production
Plasma 1, 25 vitamin D3 Has immunosuppressive and anti-inflammatory properties and levels are low in 
metabolic syndrome and rheumatological conditions
Acetylcholinesterase and butyrylcholinesterase Their activity indicates the vagal tone and the amount of acetylcholine released 
and indirectly serve as markers of inflammation as acetylcholine is an anti-
inflammatory molecule
a7nAChR expression on peripheral macrophages and  
synovial fibroblasts
a7nAChR expression may indicate the status of cholinergic anti-inflammatory 
pathway and could be used to assess response to therapy as prognostic marker
Catecholamines in peripheral leukocytes Catecholamines have proinflammatory action and suggest their role and 
contribution to inflammationJournal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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and immunosuppressive drugs (such as cyclosporine, cyclo-
phosphamide, and azathioprine). Although there have been 
significant advances in the management of autoimmune 
diseases by the use of these drugs, especially biologics, their 
actions are often unpredictable: Not all patients respond 
adequately to these therapeutic approaches; moreover, sig-
nificant side effects might result. Hence, as suggested above, 
newer therapeutic approaches are needed.
It is possible that GIK, EP, lipid-enriched albumin, 
VNS, PUFAs and their products LXs, resolvins, protectins, 
and ghrelin altogether may not be able to produce adequate 
immunosuppression and anti-inflammatory actions that 
lead to amelioration of the disease process in lupus, RA, 
and other autoimmune diseases. It is recommended that 
some of these suggested approaches could be performed in 
combination with the currently available therapeutic drugs. 
For example, GIK regimen, ethylpyruvate, lipid-enriched 
albumin, VNS, LXs, resolvins, protectins and their synthetic 
analogs, and ghrelin could be tried in combination with 
nonsteroidal anti-inflammatory compounds, chloroquine 
(hydroxychloroquine), corticosteroids (oral or parenteral), 
d-penicillamine, sulfasalazine, methotrexate, anti-TNF anti-
bodies, and immunosuppressive drugs (such as cyclosporine, 
cyclophosphamide, and azathioprine). Another option that 
could be investigated is the use of anti-TNF-α and other bio-
logics in combination (as a complex or separately) with EP, 
ghrelin, PUFAs, LXs, resolvins and protectins, and insulin 
and be used as parenteral infusion. All these permutations 
and combinations need to be tried both in the animal models 
of various autoimmune diseases and other inflammatory con-
ditions and in the clinic before knowing which therapeutic 
approach is of significant benefit to these patients. With such 
an approach, one can measure various plasma tissue factors, 
as shown in Table 1, to determine the effectiveness of the 
therapeutic approach employed.
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